KemPharm Inc (KMPH)’s Stock Is Buy After Today’s Significant Increase

September 17, 2017 - By Hazel Jackson

The stock of KemPharm Inc (NASDAQ:KMPH) is a huge mover today! The stock increased 5.97% or $0.2 on September 15, reaching $3.55. About 110,033 shares traded or 18.21% up from the average. KemPharm Inc (NASDAQ:KMPH) has declined 32.16% since September 17, 2016 and is downtrending. It has underperformed by 48.86% the S&P500.
The move comes after 6 months positive chart setup for the $52.03M company. It was reported on Sep, 17 by Barchart.com. We have $3.87 PT which if reached, will make NASDAQ:KMPH worth $4.68M more.

Analysts await KemPharm Inc (NASDAQ:KMPH) to report earnings on November, 8. They expect $-0.69 earnings per share, up 25.00 % or $0.23 from last year’s $-0.92 per share. After $-0.44 actual earnings per share reported by KemPharm Inc for the previous quarter, Wall Street now forecasts 56.82 % negative EPS growth.

KemPharm Inc (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 14 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, September 18 by Oppenheimer. The firm has “Buy” rating by Roth Capital given on Wednesday, June 28. The company was maintained on Thursday, August 10 by Oppenheimer. The firm earned “Buy” rating on Tuesday, December 20 by Canaccord Genuity. The company was maintained on Friday, May 6 by RBC Capital Markets. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, August 10. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, August 14. Roth Capital maintained it with “Buy” rating and $800 target in Friday, August 11 report. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, September 17 report. Canaccord Genuity maintained KemPharm Inc (NASDAQ:KMPH) on Monday, September 11 with “Buy” rating.

More notable recent KemPharm Inc (NASDAQ:KMPH) news were published by: Globenewswire.com which released: “KemPharm, Inc. Reports Second Quarter 2017 Results” on August 10, 2017, also Globenewswire.com with their article: “KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and …” published on March 27, 2017, Marketwatch.com published: “3.60” on April 16, 2015. More interesting news about KemPharm Inc (NASDAQ:KMPH) were released by: Globenewswire.com and their article: “KemPharm Announces FDRR Process Completion and Resubmission of the Apadazâ„¢ NDA” published on September 12, 2017 as well as Prnewswire.com‘s news article titled: “Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics …” with publication date: October 26, 2016.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The company has market cap of $52.03 million. The Firm is engaged in the discovery and development of prodrugs. It currently has negative earnings. The Firm uses its Ligand Activated Therapy platform technology to create prodrugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.